Advertisement

 

 

Molecular monitoring of chronic myeloid leukemia: present and future.

Molecular monitoring of chronic myeloid leukemia: present and future.
Author Information (click to view)

Yeung CC, Egan D, Radich JP,


Yeung CC, Egan D, Radich JP, (click to view)

Yeung CC, Egan D, Radich JP,

Advertisement
Share on FacebookTweet about this on TwitterShare on LinkedIn

Expert review of molecular diagnostics 2016 8 23()

Abstract
INTRODUCTION
Fusion of BCR-ABL1 genes causes chronic myeloid leukemia (CML). As a reliable marker of disease burden, it also serves as the target of tyrosine kinase inhibitors (TKIs). New more sensitive molecular diagnostic tools for BCR-ABL1 can contribute to therapeutic decision-making, especially in considering drug discontinuation for patients enjoying prolonged deep molecular response.

AREAS COVERED
Several novel platforms are transforming CML molecular diagnostics to enable faster point-of-care devices, better understanding of clonal diversity and resistance mutations. Here, we review these molecular platforms, knowing implementation in other hematological malignancies will ensue. Expert commentary: Treatment with TKI in CML is the first example of a highly effective targeted therapy. Monitoring of BCR-ABL1 mRNA is standard in assessing disease burden being highly predictive of outcomes recommended by both ELN and NCCN; however, studies has demonstrated poor adherence to these recommendations. In both clinical practice and assay performance, further optimizing of BCR-ABL1 monitoring can be envisioned including point-of-care methods for increased availability of rapid, standardized testing and increasingly sensitive molecular assays that allow for quantification of MRD and detecting resistance mutations.

Submit a Comment

Your email address will not be published. Required fields are marked *

5 × 5 =

[ HIDE/SHOW ]